Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Microsoft — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Microsoft trades at $531.14 (market cap $4.04T). The key difference: Microsoft is far larger — about 455.5× Kymera Therapeutics Inc. Common Stock's market cap, and Microsoft pays a 0.72% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Microsoft for 142 Days on average.
| KYMR | MSFT | |
|---|---|---|
Market Cap | $8.87B | $4.04T |
Volume | 779,107 | 23,799,223 |
Sector | Health | Technology |
52-Week High | $127.31 | $543.45 |
52-Week Low | $55.80 | $352.83 |
Typical Hold Time | 0 Days | 142 Days |
Enterprise Value | $8.26B | $4.02T |
Dividend Yield | — | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Microsoft (MSFT) trades at $533.69, down 1.38% today but maintains strong fundamentals with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $530 and resistance at $544, while valuation metrics like P/E of 30.28 reflect premium pricing. Recent analyst coverage remains overwhelmingly positive with 82% buy ratings and a $574.50 consensus price target, indicating 7.6% upside potential from current levels.
Outlook remains favorable with AI-driven growth catalysts from Azure and Copilot, though risks include elevated capital expenditures and competitive pressures. The company's strong cash flow generation ($136.16B operating cash flow in 2025) and declining debt-to-asset ratio (6.97% in 2025) provide financial stability. Investors should monitor Q3 2026 earnings against the $4.72 EPS expectation for continued momentum validation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
